Drug Trial Radar · NCT06410924
A Study to Evaluate DD01 in Overweight/Obese Subjects With MASLD/MASH
Last checked: Nov 19, 2026Latest source record: May 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
67
Actual
Start
Jun 13, 2024
Primary completion
May 20, 2025
Study completion Apr 21, 2026
Sponsor
- Lead sponsor
- Neuraly, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 13, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2 Study to evaluate the effect of DD01 treatment in overweight/obese patients with metabolic dysfunction-associated steatotic liver disease (MASLD)/metabolic dysfunction-associated steatohepatitis (MASH).
Conditions
- NAFLD
- NASH
Interventions
DD01Drug
Dual GLP-1 and glucagon receptor agonist
PlaceboDrug
Placebo matching DD01
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of subjects who achieve at least 30% liver fat reduction measured by MRI-PDFFTime frame: 12 weeks
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
Summit Research Site
Maitland, Florida
Summit Research Site
Monroe, Louisiana
Summit Research Site
West Monroe, Louisiana
Summit Research Site
Kansas City, Missouri
Summit Research Site
Austin, Texas
Summit Research Site
Bellaire, Texas
Summit Research Site
Brownsville, Texas
Summit Research Site
Corpus Christi, Texas
Summit Research Site
Edinburg, Texas
Summit Research Site
Georgetown, Texas
Summit Research Site
San Antonio, Texas
Summit Research Site
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.